## **TOPotecan / CISplatin**







Printed: 13/May/2020

Kuwait	Cancer Con	trol Center	* T O P C I S - O O -		<b>ⅢⅢ</b> Ministry of Hea	
Name: Nationality: Gender/Age:			File Civ DO	Ht (cm): Wt (Kg): BSA (m²):		
		ıll Cell Lung C vailable □	ancer (Subsequent Line). NA <b>Alle</b>	rgies: 🗆 NKA	☐ Yes, specify;	
Paramete	rs: Initia	ite treatment o	only if ANC ≥ 1000; HB ≥ 8	80; PIt ≥ 100,000;	CrCl > 45 ml/min.	
Ondan		8 mg P(		eatment)		
Standard	Protoco	l:				
DRUG DO		OSE	ADMINISTRATION		DAYS	
TOPoted	can 1	mg/m² IV in 100 mL NS o		L NS over 30 min	. D1, 2, 3, 4, 5	
CISplatin		75 mg/m² IV in 100		nL NS over 60 mii	n. D5	
To be re	peated e	very 4 weeks	s for 6 cycles.			
Treatmen Pre-hyd	-		<cl +="" 20="" 8="" meq="" mgso₄="" td="" π<=""><td>Eq IV over 1 hrs.</td><td></td></cl>	Eq IV over 1 hrs.		
Cycle	Day	Date	TOPotecan		CISplatin	
C#	D1				XXXXXX	
	D2				xxxxxx	
	D3				XXXXXX	
	D4				XXXXXXX	
	D5					
Post-hy	dration:	1 Liter NS IV	over 1 hrs followed by 150	mL Mannitol 20%	6 IV bolus.	
Important Report		3/4 toxicities:	☐ None ☐ Hematol	ogical □ Non-H	ematological	
If yes;		dicate hospita		′es □ No ′es □ No		
Did it indicate dose reduction? ☐ Yes ☐ No						
	Did it in	dicate G-CSF	support?	′es □ No		
Physician (Stamp and signature)				Consultant (Stamp and signature)		